10/13/2026
A PRADA II substudy in explores the effects of sacubitril/valsartan beyond LV systolic function in women receiving anthracycline-based therapy for breast cancer. 🎗️
Aim: To assess whether sacubitril/valsartan may preserve RV systolic and LV diastolic function during anthracycline-based therapy.
Population: 138 women with breast cancer receiving anthracycline-based chemotherapy ± trastuzumab, randomized to sacubitril/valsartan or placebo, initiated before the first anthracycline dose and continued for 18 months.
In this prespecified analysis, sacubitril/valsartan was associated with a more favorable trajectory of RV systolic function, w/ a significant benefit in RV S′ and a consistent favorable signal in RV free-wall strain. Interestingly, conventional parameters such as TAPSE, FAC, and LVEF did not differ between groups.
Regarding LV diastolic function, favorable changes were observed in mitral e′ velocity and E/A ratio, while E/e′, LAVI, and TR velocity did not differ between groups, and no patient developed diastolic dysfunction during follow-up.
💡An interesting reminder of the potential value of looking beyond LVEF when assessing subclinical cardiac changes during cancer therapy, while we still need larger studies to understand whether these subtle changes translate into meaningful clinical benefit.
https://bit.ly/4jSy00K
